Abbott Laboratories (VIE:ABT)

Austria flag Austria · Delayed Price · Currency is EUR
93.34
+3.05 (3.38%)
At close: Feb 2, 2026
-24.19%
Market Cap160.47B -16.1%
Revenue (ttm)37.75B +5.7%
Net Income5.56B -51.3%
EPS3.17 -51.3%
Shares Outn/a
PE Ratio28.88
Forward PE19.09
Dividend2.07 (2.22%)
Ex-Dividend DateJan 15, 2026
Volumen/a
Average Volume18
Open91.86
Previous Close90.29
Day's Range91.86 - 93.34
52-Week Range88.59 - 134.20
Betan/a
RSI31.33
Earnings DateJan 22, 2026

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 1888
Employees 115,000
Stock Exchange Vienna Stock Exchange
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.52 billion, a decrease of -51.13%.

Financial numbers in USD Financial Statements